免疫腫瘤藥物市場規模、佔有率、成長分析（按治療類型、疾病類型、分銷管道和地區）-產業預測，2025-2032

2023年，免疫腫瘤藥物的全球市場規模為230.2億美元，從2024年的272.6億美元成長到2032年的1052.6億美元，預計在預測期內（2025-2032年）將以複合年成長率成長。 18.4%。

免疫腫瘤學 (IO) 藥物因其個人化方法而在癌症治療中取得了進展，該方法根據患者的遺傳特徵和腫瘤特徵量身定做治療。與傳統治療相比，這種有針對性的策略可以最大限度地減少副作用並改善患者的整體治療結果。 IO 藥物的主要優點包括提高存活率、減少副作用以及長期緩解的可能性。這是因為該藥物能夠刺激免疫系統選擇性地識別和破壞癌細胞，從而保護健康組織。 IO 療法的持續療效非常顯著，患者報告由於併發症較少而改善了生活品質，並且它對多種癌症（包括黑色素瘤和肺癌）患者顯示出持續療效。這種能力代表了有效管理癌症作為一種慢性疾病並改善患者長期福祉的變革性轉變。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析
• 監管分析
• 案例研究分析
• 專利分析

按治療類型分類的免疫腫瘤藥物市場規模

• 市場概況
• 免疫查核點抑制劑
• 免疫系統調節劑
• 癌症疫苗
• 溶瘤病毒
• 其他

按疾病類型分類的免疫腫瘤藥物市場規模

• 市場概況
• 惡性黑色素瘤
• 肺癌
• 血癌
• 腎臟細胞癌
• 攝護腺癌
• 膀胱癌
• 其他

免疫腫瘤藥物市場規模：依通路分類

• 市場概況
• 醫院藥房
• 零售藥房
• 網路藥房

免疫腫瘤藥物市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2022-2024）

主要企業簡介

• Coloplast Corp（Denmark）
• Bristol Myers Squibb Company（US）
• Novartis AG（Switzerland）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Merck & Co., Inc.（US）
• GSK Plc.（UK）
• Eli Lilly and Company（US）
• Fresenius Kabi AG（Germany）
• Pfizer Inc.（US）
• AbbVie Inc.（US）
• Genentech Inc.（US）
• Sanofi（France）
• AstraZeneca（UK）
• Bayer AG（Germany）
• Bluebird Bio, Inc.（US）
• Regeneron Pharmaceuticals, Inc.（US）
• Amgen Inc.（US）
• Johnson & Johnson（US）
• Merck KGaA（Germany）
• Ipsen（France）

結論和建議

Global Immuno-Oncology Drugs Market size was valued at USD 23.02 billion in 2023 and is poised to grow from USD 27.26 billion in 2024 to USD 105.26 billion by 2032, growing at a CAGR of 18.4% during the forecast period (2025-2032).

Immuno-Oncology (IO) drugs are gaining traction in cancer treatment due to their personalized approach, which aligns therapy with patients' genetic profiles and tumor characteristics. This targeted strategy minimizes side effects compared to conventional treatments, enhancing overall patient outcomes. Key advantages of IO drugs include increased survival rates, reduced adverse effects, and potential for long-term remission, driven by the drugs' ability to stimulate the immune system to selectively identify and destroy cancer cells, sparing healthy tissue. As patients report improved quality of life with fewer complications, the enduring effectiveness of IO therapies is noteworthy-showing sustained responses in patients with various cancers, including melanoma and lung cancer. This capability signifies a transformative shift towards managing cancer as a chronic condition effectively and improving long-term patient welfare.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Immuno-Oncology Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Immuno-Oncology Drugs Market Segmental Analysis

Global Immuno-Oncology Drugs Market is segmented by treatment type, disease type, distribution channel and region. Based on treatment type, the market is segmented into immune checkpoint inhibitors, immune system modulators, cancer vaccines, oncolytic virus and others. Based on disease type, the market is segmented into melanoma, lung cancer, blood cancer, renal cell carcinoma, prostate cancer, bladder cancer and others. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Immuno-Oncology Drugs Market

One of the primary catalysts for growth in the Global Immuno-Oncology Drugs market is the approval of these drugs by regulatory agencies. The endorsement from entities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) is crucial, as it validates the safety and efficacy of the drugs, allowing them to be marketed and utilized in clinical settings. These approvals signify a positive outlook for the market, attracting investments from pharmaceutical companies eager to develop new immuno-oncology treatments. As more drugs receive regulatory green lights, healthcare providers gain access to innovative therapies, ultimately improving patient outcomes and fostering further advancements in the field. This dynamic underscores the vital role regulatory approvals play in shaping the immuno-oncology landscape.

Restraints in the Global Immuno-Oncology Drugs Market

The growth of the global immuno-oncology drugs market faces significant challenges primarily due to their high costs. These treatments are often prohibitively expensive, creating financial burdens for both patients and healthcare systems. The exorbitant prices can deter adoption, particularly in regions with limited access to affordable healthcare, adversely impacting market expansion. Moreover, the steep costs may dissuade insurance companies and government healthcare programs from providing coverage, leading to further restrictions on patient access to these essential therapies. Consequently, the high pricing of immuno-oncology drugs stands as a substantial barrier to market growth and patient treatment options.

Market Trends of the Global Immuno-Oncology Drugs Market

The Global Immuno-Oncology (IO) Drugs market is witnessing a significant trend towards the development and integration of biomarkers, enhancing the precision of cancer treatments. Biomarkers enable healthcare professionals to identify patients who are most likely to benefit from immuno-oncology therapies, facilitating personalized treatment approaches. This trend not only improves patient selection and therapeutic outcomes but also minimizes adverse effects by excluding those unlikely to respond. As research advances in identifying new biomarkers, the IO drug market is poised for growth, driving innovations that lead to safer and more effective cancer treatments and ultimately transforming patient care landscapes worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Case Study Analysis
• Patent Analysis

Global Immuno-Oncology Drugs Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Immune Checkpoint Inhibitors
• Immune System Modulators
• Cancer Vaccines
• Oncolytic Virus
• Others

Global Immuno-Oncology Drugs Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Melanoma
• Lung Cancer
• Blood Cancer
• Renal Cell Carcinoma
• Prostate Cancer
• Bladder Cancer
• Others

Global Immuno-Oncology Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Immuno-Oncology Drugs Market Size & CAGR (2025-2032)

• North America (Treatment Type, Disease Type, Distribution Channel)
  • US
  • Canada
• Europe (Treatment Type, Disease Type, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Disease Type, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Disease Type, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Disease Type, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Coloplast Corp (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK Plc. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bluebird Bio, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations